Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ridgeback Biotherapeutics

- PMLiVE

FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine

Vaccine can be transported/stored at standard pharmaceutical freezer temperatures

regeneron headquarters

UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’

CHMP has now adopted a positive opinion for the treatment

- PMLiVE

FDA briefing document backs J&J’s one-dose COVID-19 vaccine

Company is seeking an emergency use authorisation in the US

- PMLiVE

Moderna announces plans for COVID-19 variant-specific booster jabs and new production targets

Company is developing variant-specific COVID-19 vaccine candidate

- PMLiVE

Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds

Study included around 1.2 million people in Israel

- PMLiVE

FDA updates guidance for COVID-19 vaccine makers addressing new variants

FDA said that it expects manufacturing information for modified vaccines to remain generally the same

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

- PMLiVE

Reaching patients and HCPs during the pandemic

COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels

Looking back at the year when everything changed

COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families.

Impetus Digital

- PMLiVE

WHO agrees to no-fault compensation for rare serious side effects from COVAX-distributed vaccines

The no-fault compensation fund will be accessible via a web portal by 31 March 2021

- PMLiVE

EU set to contribute €1bn to COVAX

EU had already pledged €500m to the international vaccine-sharing facility

- PMLiVE

First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%

COVID-19 vaccines are also reducing risk of hospitalisation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links